Molecular mechanisms of lung‑specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors (Review)

Sakao,Seiichiro; Tatsumi,Koichiro

doi:10.3892/ol.2012.872

Molecular mechanisms of lung‑specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors (Review)

Authors:
- Seiichiro Sakao
- Koichiro Tatsumi
View Affiliations

Affiliations: Department of Respirology (B2), Graduate School of Medicine, Chiba University, Chuo‑ku, Chiba 260‑8670, Japan
Published online on: August 21, 2012 https://doi.org/10.3892/ol.2012.872
Pages: 865-867

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung‑specific toxicity induced by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of non‑small cell lung cancer (NSCLC) has emerged as a critical side-effect. Although the clinical features of the pulmonary side-effects of TKIs have been characterized, the details of the molecular mechanisms in the development of this lung‑specific toxicity remain to be elucidated. EGFR‑dependent epithelial regeneration and restoration plays an important role in the recovery process from lung injury. The lung comprises a unique environment where epithelial cells are exposed to internal agents in the systemic circulation and to airborne particles through the mouth and nose. This unique environment may also be associated with the development of lung‑specific toxicity induced by EGFR‑TKIs. Therefore, the aim of this review was to provide further insight into the molecular mechanisms of lung‑specific toxicity in the context of treatment with EGFR‑TKIs.

View Figures

View References

1.	A InoueY SaijoM MaemondoSevere acute interstitial pneumonia and gefitinibLancet361137139200310.1016/S0140-6736(03)12190-312531582
2.	D MakrisA ScherpereelM CopinFatal interstitial lung disease associated with oral erlotinib therapy for lung cancerBMC Cancer7150200710.1186/1471-2407-7-15017683587
3.	V LiuD WhiteM ZakowskiPulmonary toxicity associated with erlotinibChest13210421044200710.1378/chest.07-005017873198
4.	M AndoI OkamotoN YamamotoPredictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinibJ Clin Oncol2425492556200610.1200/JCO.2005.04.986616735708
5.	CL ChouHW KoCW WangCT YuHP KuoCD HuangErlotinib-associated near-fatal interstitial pneumonitis in a patient with relapsed lung adenocarcinomaChang Gung Med J33100105201020184801
6.	B VahidA EsmailiErlotinib-associated acute pneumonitis: report of two casesCan Respir J Can Thorac Soc14167170200717464382
7.	Y Del CastilloP EspinosaF BodíInterstitial lung disease associated to erlotinib treatment: a case reportCases J359201020509858
8.	I DimopoulouA BamiasP LyberopoulosMA DimopoulosPulmonary toxicity from novel antineoplastic agentsAnn Oncol17372379200610.1093/annonc/mdj05716291774
9.	MM PeerzadaTP SpiroHA DawPulmonary toxicities of tyrosine kinase inhibitorsClin Adv Hematol Oncol9824836201122252615
10.	JH MinHY LeeH LimDrug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insightCancer Chemother Pharmacol6810991109201110.1007/s00280-011-1737-221913033
11.	TS MokYL WuS ThongprasertGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med361947957200910.1056/NEJMoa081069919692680
12.	M MaemondoA InoueK KobayashiGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med36223802388201010.1056/NEJMoa090953020573926
13.	TJ LynchDW BellR SordellaActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med35021292139200410.1056/NEJMoa04093815118073
14.	JG PaezPA JanneJC LeeEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience3041497500200410.1126/science.109931415118125
15.	R SordellaDW BellDA HaberJ SettlemanGefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathwaysScience30511631167200410.1126/science.110163715284455
16.	MH CohenJR JohnsonR PazdurU.S. food and drug administration drug approval summary: conversion of imatinib mesylate (sti571; gleevec) tablets from accelerated approval to full approvalClin Cancer Res111219200515671523
17.	K TakeuchiF ItoReceptor tyrosine kinases and targeted cancer therapeuticsBiol Pharm Bull3417741780201110.1248/bpb.34.177422130229
18.	L RicheldiU CostabelM SelmanEfficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosisN Engl J Med36510791087201110.1056/NEJMoa110369021992121
19.	BA KeoghRG CrystalAlveolitis: the key to the interstitial lung disordersThorax37110198210.1136/thx.37.1.17041320
20.	TE King JrA PardoM SelmanIdiopathic pulmonary fibrosisLancet37819491961201110.1016/S0140-6736(11)60052-4
21.	WS ChenCS LazarM PoenieRequirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptorNature328820823198710.1038/328820a03498122
22.	Y YardenMX SliwkowskiUntangling the ErbB signalling networkNat Rev Mol Cell Biol2127137200110.1038/3505207311252954
23.	H SuzukiK AoshibaN YokohoriA NagaiEpidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosisCancer Res6350545059200312941834
24.	DK MadtesHK BusbyTP StrandjordJG ClarkExpression of transforming growth factor-alpha and epidermal growth factor receptor is increased following bleomycin-induced lung injury in ratsAm J Respir Cell Mol Biol11540551199410.1165/ajrcmb.11.5.75245667524566
25.	M SelmanTE KingA PardoAmerican Thoracic Society; European Respiratory Scoiety; American College of Chest PhysiciansIdiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapyAnn Intern Med134136151200110.7326/0003-4819-134-2-200101160-0001511177318
26.	RP BaughmanEE LowerMA MillerPA BejaranoSC HeffelfingerOverexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosisSarcoidosis Vasc Diffuse Lung Dis165761199910207942
27.	WD HardieDR ProwsA Piljan-GentleDose-related protection from nickel-induced lung injury in transgenic mice expressing human transforming growth factor-alphaAm J Respir Cell Mol Biol26430437200210.1165/ajrcmb.26.4.459411919079
28.	BR SmithWR BrianThe role of metabolism in chemical-induced pulmonary toxicityToxicol Pathol19470481199110.1177/0192623391019004151813990
29.	FP GuengerichPurification and characterization of xenobiotic-metabolizing enzymes from lung tissuePharmacol Ther45299308199010.1016/0163-7258(90)90068-D2405438
30.	TR DevereuxBA DominRM PhilpotXenobiotic metabolism by isolated pulmonary cellsPharmacol Ther41243256198910.1016/0163-7258(89)90109-52652151
31.	RA RothJF ReindelLung vascular injury from monocrotaline pyrrole, a putative hepatic metaboliteAdv Exp Med Biol283477487199110.1007/978-1-4684-5877-0_641906225
32.	DE WilliamsRL ReedG KedzierskiGA DannanFP GuengerichDR BuhlerBioactivation and detoxication of the pyrrolizidine alkaloid senecionine by cytochrome P-450 enzymes in rat liverDrug Metab Dispos1738739219892571477
33.	D McKillopAD McCormickA MillarGS MilesPJ PhillipsM HutchisonCytochrome P450-dependent metabolism of gefitinibXenobiotica353950200510.1080/0049825040002646415788367
34.	J LiM ZhaoP HeM HidalgoSD BakerDifferential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymesClin Cancer Res37313737200710.1158/1078-0432.CCR-07-008817575239